Big Pharma and Biotech’s are looking at alternative routes of dministration for proteins (e.g., monoclonal antibodies) and oligonucleotides (e.g. Antisense Oligonucleotides) to treat diseases of the respiratory tract.
A plethora of well-established inhalation devices and formulation technologies can be optimized to enable the aerosolization of proteins and oligonucleotides, at the same time not impacting the structures of these entities and maintaining efficacy.
Traditionally, small molecules have been dominating the market of inhaled drugs. Therefore, contract testing organizations specialized in testing these drugs mostly have labs, capable of testing small molecules.
With our +15 years of experience in the field of inhaled drug testing, as well as +20 years of protein and +10 years of nucleic acid QC-testing, we bring the required knowhow to the table to make your inhaled protein or oligonucleotide project a success.
Put our inhaled drug testing and decades of experience in protein and nucleic acid QC-analysis to the test!
More information:
Dr. Steven A. Watt
email: steven.watt@am-labor.de
phone: +49 (0)2271 7559 100